Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of XTMAB-16 in Pulmonary Sarcoidosis
NCT06169397Phase 2Completed
- Sponsor
- Xentria
- Start
- Mar 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of xtmab-16 in pulmonary sarcoidosis, sponsored by Xentria. Started Mar 2024; status: completed.
02
Drugs
xtmab-16
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT06169397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169397.